62 results about "Chemoprophylaxis" patented technology

Novel compounds useful as chemotherapeutic and chemopreventive agents are provided. The compounds are analogs of polyphenol catechins that occur in green tea, such as epigallocatichin-3-gallate (EGCG), and have the structure of formula (I)wherein R1 through R11 are defined herein. Preferred R4 moieties are selected from O, S, NH and CH2, and in exemplary compounds, R4 is O and R5 is a tri-substituted aroyloxy substituent, such as a 3,4,5-substituted benzoyloxy group. Pharmaceutical compositions are provided as well, as are methods of chemotherapy and chemoprevention.

The invention relates to an application of a tanshinone compound in preparing anti-tumor medicaments, and the prepared medicaments can resist tumors, such as brain tumors, lung cancer, liver caner, breast cancer, prostatic cancer, pancreatic cancer, cervical cancer, gastric cancer, esophagus cancer, and the like. Proved by experiments, the tanshinone compound is concentration-dependent to suppress the proliferation of tumor cells. The compound can obviously induce the expression of quinone reductase and obviously suppress the generation of tumor vessels, thus the compound can also be used for preparing cancer chemical prevention medicaments, anti-inflammatory medicaments and medicaments for suppressing the generation of the tumor vessels. Frequently used low-price reagents, such as alcohol, chloroform, methanol, silica gel, and the like, are used for separating tanshinone compound monomers from medicinal materials. The method is simple and reliable, has low cost and high efficiency, can be used for carrying out industrialized mass production and is beneficial to popularization and application. The tanshinone compound has a structural general formula disclosed in the specification.

A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.

Apigenin is a nontoxic compound. The present invention is appropriate for apigenin use in people who have a high risk of getting cancer, and in people who have cancer through chemoprevention and chemotherapy, respectively. We showed that apigenin inhibited cancer cell proliferation, tumor growth and angiogenesis. Apigenin selectively inhibited proliferation and induced apoptosis of cancer cells, enhanced the sensitivity of different cancer cells to different therapeutic drugs including cisplatin and taxol. Apigenin also inhibits angiogenesis and tumor growth in human cancers, and inhibits angiogenic inducers such as hypoxia-inducible factor 1 (HIF-1) and vascular endothelial growth factor (VEGF). Apigenin inhibited expression of HIF-1 and VEGF through PI3K, AKT, p70S6K1 and HDM2 pathways, which are commonly observed in all kinds of human cancers. Thus, our results indicate that apigenin can be applied to various human cancers for chemoprevention, and for chemotherapy when combined with other therapeutic reagents.

Aromatase inhibitors (AIs) are disclosed which are useful in the treatment and prevention of post-menopausal breast cancer. New AIs derived from natural products are disclosed that are evaluated for clinical utility for treating post-menopausal breast cancer and may also act as chemopreventive agents for preventing breast cancer. Several pure compounds demonstrated AI activity using a noncellular, enzyme-based microsomal and a cell-based aromatase assay. Correlations are made between structural classes with levels of aromatase inhibition. The disclosure may be utilized to direct synthetic modification of natural product scaffolds to enhance aromatase inhibition or to standardize botanical dietary supplements for increased aromatase inhibition activity.

The present invention provides the chemopreventive agent deguelin, a natural product isolated from Mundulea serica (Leguminosae), and derivatives thereof, for use in combination with a second agent for inhibiting growth premalignant and malignant lung cancer cells by causing G2 / M arrest and apoptosis. Thus, the present invention provides deguelin-based combination therapies for the treatment and prevention of lung cancer. The second agent of the present invention may, in particular, be an inhibitor of the P13K, MAPK or JNK signaling pathways, or a chemotherapeutic agent, or radiotherapeutic agent.

A long-acting antimicrobial medical oil emulsion belongs to a long-acting antimicrobial medical dosage form and comprises aqueous phase with antimicrobial medicine, oil phase, emulsifier and stabilizer, wherein the oil phase adopts 7# or 15# of white oil, the aqueous phase emulsifier is Tween-80, the oil phase emulsifier is Span-80; and the aqueous phase is covered by oil to be dispersed in the oil phase. The dosage form can fully control the release of the antimicrobial action of active ingredients of the antimicrobial medicine, save the breeding cost, reduce the environmental pollution, and the like; and the dosage form is suitable for the preparation of active ingredients of various water-soluble or oil-soluble antimicrobial medicines. The invention provides the corresponding technical support for healthy raise in aspects of chemoprophylaxis and treatment of diseases.

The invention specifically relates to application of losmapimod to non-small cell lung cancer, belonging to the field of chemoprophylaxis of tumors. Losmapimod and a tyrosine kinase receptor inhibitorfor non-small cell lung cancer are combined and applied to non-small cell lung cancer, so tumor cells are enhanced in sensibility to the tyrosine kinase receptor inhibitor for non-small cell lung cancer, and formation of drug resistance is delayed. In the invention, it is proved for the first time that formation of gefitinib-resistant cell strains and gefitinib resistance is dependent on formation of tetraploid cells. When losmapimod and gefitinib are applied to tumor cells of non-small cell lung cancer together, tumor cells are obviously enhanced in sensibility to gefitinib, and multiplication and clone formation capabilities of tumor cells are inhibited; and thus, when gefitinib is applied to treatment of non-small cell lung cancer, the occurrence of gefitinib resistance is delayed, andthe application effect of gefitinib in treatment of non-small cell lung cancer is enhanced.

Compounds of general formula (I), wherein from A1 to A5, and from B1 to B5 are H, alkyl, alkoxyl, halogen, carboxylic derivatives or sulfur derivatives, among others; and from P1 to P3 are H, halogen, alkyl or alkoxyl, among others. Said compounds may be used for the chemoprevention and treatment of both precancerous lesions and cancer.

The invention relates to a method for extracting and purifying sesquiterpene coumarin aether in the field of chemical technology, which comprises the steps as follows: step 1: southernwood roots are smashed and ultrasonically extracted with methanol; the extracting solution is rotary-evaporated and condensed to obtain extract which is then delaminated by adopting acetic ether and water double-phase dispersion and extraction; the acetic ether organic phase of an upper layer is taken as an extracting concentrate; step 2: column chromatography is carried out after the extracting concentrate is added with an adsorbent; elution is carried out by using petroleum ether and acetic ether mixed eluant, and then thin-layer chromatography is carried out to collect components containing the sesquiterpene coumarin aether; step 3: the concentrate is furthered condensed to the extract which is then dispersed with methanol of same volume and then filtered with a nylon membrane, purified with the reversed-phase column of a preparative liquid phase ODS RP-C18 and eluted with mixture solution of methanol and water; and finally, the corresponding components are condensed. The invention has simple preparation method and easily available raw materials for preparation and can be applied to chemoprophylaxis and cure of tumors and development of relevant antitumor drugs.

The invention discloses a pharmaceutical composition. The pharmaceutical composition is characterized by comprising a ginsenoside monomer and bicyclol. The pharmaceutical composition has a remarkablecurative effect on chemoprevention and treatment of liver cancer, and has remarkable synergistic and synergistic effects compared with the ginsenoside monomer or bicyclol used alone. The invention further discloses application of the ginsenoside monomer and bicyclol in preparation of the pharmaceutical composition for preventing and / or treating tumors and application of the ginsenoside monomer inpromotion of the effect of the pharmaceutical composition for preventing and / or treating tumors.

The present invention refers to compounds of formula (I):as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and / or chemoprevention of cancer, aging related diseases or processes, diabetes and neurodegenerative diseases.

The present invention is directed to intrauterine devices that release progestins or an inflammatory cytokine after placement. These devices can be used to reduce the risk of a woman developing endometrial cancer. The invention is also directed to therapeutic methods in which a sample of uterine cells obtained from a woman is assayed to determine the extent to which PTEN null clones (latent endometrial precancers) are present. In cases where the number of such null clones is high, the woman is administered an intrauterine device that releases either a progestin or an inflammatory cytokine.

Low-coherence interferometry (LCI) techniques enable acquisition of structural and depth information of a sample. A “swept-source” (SS) light source may be used. The swept-source light source can be used to generate a reference signal and a signal directed towards a sample. Light scattered from the sample is returned as a result and mixed with the reference signal to achieve interference and thus provide structural information regarding the sample. Depth information about the sample can be obtained using Fourier domain concepts as well as time domain techniques. In another embodiment, an a / LCI system and method is provided that is based on a time domain system and employs a broadband light source. The systems and processes disclosed herein can be used for biomedical applications, included measuring cellular morphology in tissues and in vitro, as well as diagnosing intraepithelial neoplasia, and assessing the efficacy of chemopreventive and chemotherapeutic agents.

The disclosure provides, among other things, a method of decreasing resistance to the chemopreventive properties of non-steroidal anti-inflammatory agents, e.g., celecoxib, particularly in the prevention of cancer, e.g., colon cancer, by increasing the levels or activity of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). The disclosure also provides a method of identifying compounds that upregulate or reactivate 15-PGDH. The disclosure also provides a method of identifying an individual suitable for treatment with a non-steroidal anti-inflammatory agent in the treatment or prevention of colon cancer.

The invention relates to an anti-inflammatory and chemopreventive composition which comprises carob products, especially carob fiber. The invention further relates to a process for producing these compositions and to the use thereof with the aim of reducing the risk, the prevention, the prophylaxis and the treatment of inflammatory disorders or cancers, especially of the gastrointestinal tract.

A method for preventing or treating colorectal cancer in a patient possessing human tropomyocin isoform TC22 is presented. Also presented is a method for evaluating TC22 expression reduction activity of a compound.

The invention provides compositions and methods for radio protection and chemo prevention using therapeutic and prophylactics methods of using (S,S)-SDG (R,R)- SDG, (S,R)-SDG (R,S)-SDG, SDG, SECO, EL, ED, analogs thereof, stereoisomers thereof and other related molecules. In one aspect, the invention relates to a method for protecting a biomolecule(such as genetic material like a nucleic acid, a protein or a lipid), a cell, or a tissue, from radiation damage in a subject in need thereof, the method comprising administering to said subject an effective amount of flaxseed, its bioactive ingredient, degradant or a metabolite thereof.

The invention discloses application of panax notoginseng saponins in preparation of a medicine for treating or preventing colitis-related colon cancer. The invention finds that the panax notoginseng saponins have obvious chemical prevention and treatment effects on the colitis-related colon cancer; and as an active component of Xuesaitong, the safety and low toxicity of the panax notoginseng saponins are fully accepted, and a new adjuvant medication scheme is provided for clinically preventing and treating colon cancer.

Novel compounds useful as chemotherapeutic and chemopreventive agents are provided. The compounds are analogs of indole-3-carbinol metabolites wherein the structures and substituents of the compounds are selected to enhance the compounds' overall efficacy, particularly with respect to therapeutic activity, oral bioavailability, long-term safety, patient tolerability, and therapeutic window. The compounds are useful not only in treatment of cancer but also in prevention of cancer. One preferred class of the novel compounds have the structure of formula (III) wherein R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, R20, and R21 are defined herein. Pharmaceutical compositions are provided as well, as are methods of synthesis and use.

A method for automated detection, monitoring and treatment of dysplasia by analyzing 3D reconstructed images of cells obtained from a specimen includes a biological specimen classifier that classifiescells from the sputum specimen as normal or abnormal. If abnormal cells are detected, then the abnormal cells are further classified as pre-cancerous or cancerous. Pre-cancerous cells are further sub-classified as being of glandular origin or squamous origin (dysplastic cells). This information would be used to define patient therapy so that if the cells are classified as dysplastic, then a cancer chemoprevention pharmaceutical like iloprost is administered to the subject over a predetermined time period to achieve a therapeutic dosage, and if only malignant cells were found or malignant andpre-cancerous cells were found, then next steps would involve patient triage to biopsy and surgery and possibly use of a cancer chemoprevention pharmaceutical.